Back to Condition
Choroideremia
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Choroideremia

Choroideremia is an inherited genetic condition characterized by progressive vision loss that primarily affects males, starting with night blindness in childhood and eventually leading to blindness in late adulthood.

Overview

Choroideremia is a condition characterized by progressive vision loss that mainly affects males. The vision impairment in choroideremia worsens over time, but the progression varies among affected individuals. However, all individuals with this condition will develop blindness, most commonly in late adulthood.

Symptoms & Progression

The progressive vision loss associated with choroideremia typically follows a characteristic pattern:

  • Night blindness (impairment of night vision) is usually the first symptom and can occur in early childhood.
  • Tunnel vision (a progressive narrowing of the field of vision) follows the initial night blindness.
  • A decrease in the ability to see details (visual acuity) occurs as the condition progresses.

These vision problems are due to an ongoing loss of cells (atrophy) in the specialized light-sensitive tissue that lines the back of the eye (retina) and a nearby network of blood vessels (the choroid).

Frequency

The prevalence of choroideremia is estimated to be 1 in 50,000 to 100,000 people. However, it is likely that this condition is underdiagnosed because of its similarities to other eye disorders. Choroideremia is thought to account for approximately 4 percent of all blindness.

Causes

Mutations in the CHM gene cause choroideremia. The CHM gene provides instructions for producing the Rab escort protein-1 (REP-1). As an escort protein, REP-1 attaches to molecules called Rab proteins within the cell and directs them to the membranes of various cell compartments. Rab proteins are involved in the movement of proteins and organelles within cells (intracellular trafficking).

Mutations in the CHM gene lead to an absence of REP-1 protein or the production of a REP-1 protein that cannot carry out its protein escort function. This lack of functional REP-1 prevents Rab proteins from reaching and attaching (binding) to the organelle membranes. Without the aid of Rab proteins in intracellular trafficking, cells die prematurely.

The REP-1 protein is active (expressed) throughout the body, as is a similar protein, REP-2. Research suggests that when REP-1 is absent or nonfunctional, REP-2 can perform the protein escort duties of REP-1 in many of the body's tissues. Very little REP-2 protein is present in the retina, however, so it cannot compensate for the loss of REP-1 in this tissue. Loss of REP-1 function and subsequent misplacement of Rab proteins within the cells of the retina causes the progressive vision loss characteristic of choroideremia.

Associated Gene

  • CHM

Inheritance

Choroideremia is inherited in an X-linked recessive pattern. The CHM gene is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a mutation must be present in both copies of the gene to cause the disorder. Males are affected by X-linked recessive disorders much more frequently than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

In X-linked recessive inheritance, a female with one mutated copy of the gene in each cell is called a carrier. She can pass on the altered gene, but usually does not experience signs and symptoms of the disorder. Females who carry a CHM mutation may show small areas of cell loss within the retina that can be observed during a thorough eye examination. These changes can impair vision later in life.

Other Names for This Condition

  • Choroidal sclerosis
  • Progressive tapetochoroidal dystrophy
  • TCD

Frequently Asked Questions

The diagnosis is confirmed by a combination of clinical eye examination (showing characteristic retinal and choroidal atrophy), visual field testing, and genetic testing for pathogenic variants in the CHM gene. Electroretinography may be used to assess retinal function, and optical coherence tomography (OCT) helps document the extent of tissue loss.
single‑dose adeno‑associated virus (AAV) vector delivering a functional CHM gene (voretigene neparvovec) has been approved in several countries for patients with confirmed biallelic CHM mutations and sufficient viable retinal cells (usually early‑to‑mid stage disease). Eligibility is determined by retinal imaging, visual field size, and overall health; you should discuss enrollment in a specialized retinal center or clinical trial.
female carrier has a 50 % chance of passing the mutated X chromosome to each child. Sons who inherit the mutation will be affected; daughters who inherit it become carriers and may develop mild retinal changes later in life. Carrier females should have baseline ophthalmic exams and periodic retinal imaging because some develop subclinical pigmentary changes that could affect vision.
Yes. High‑contrast, large‑print reading materials, handheld magnifiers, and electronic video magnifiers can improve central tasks. For night driving, avoid low‑light conditions; use a white cane or guide dog for navigation when peripheral vision is limited. Orientation‑and‑mobility training and smartphone apps that provide audio cues for obstacles are also beneficial.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab